Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function 12 December, 5.00pm at BNZ Partners...
Day: 29 November 2018
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has granted P-BCMA-101, Poseida Therapeutics’ CAR T-cell therapy and lead product candidate,...
Expert Highlights Use of CAR T-Cell Therapy in DLBCL
There has been activity with chimeric antigen receptor (CAR) T cells in patients with relapsed diffuse large B-cell lymphoma (DLBCL),...